PDL BioPharma, Inc. PDLI

Other  —  Other
Market cap
—
P/E
0.0×
Dec '20 Jun '20 Mar '20 Dec '19 Older periods
ROE
— (28.44%) (17.45%) (10.64%)

+8 more TTM periods

ROA
0.00% (21.88%) (13.74%) (8.38%)
ROIC
— (24.38%) (17.50%) (13.82%)
Return on Tangible Assets
— (33.39%) (21.22%) (26.00%)
Average Days of Receivables
— 43.36 53.11 43.72
Free Cash Flow per Share
— (0.06) (0.38) 0.59
Free Cash Flow
— (6.85) (46.21) 70.29
Capital Expenditures
— 81.74 (0.81) 102.73
Piotroski F-Score
— 3.00 3.00 2.00
Other line items
Cash ROIC
— (16.44%) (6.56%) (4.11%)
Accounts Receivable Turnover
— 4.31 4.58 3.88
Accounts Payable Turnover
— 5.50 5.97 6.78
Inventory Turnover
— 3.49 4.04 3.97
Average Days of Payables
— 25.53 36.23 18.21
Days of Inventory on Hand
— 91.51 73.04 54.87
Tax Rate
— (0.13) (0.15) (0.04)
Research and Development Expense of Revenue
— 17.05% 15.27% 13.35%
Selling, General and Administrative Expense of Revenue
— 113.32% 107.87% 98.76%
Share Based Compensation of Revenue
— 42.29% 43.98% 13.00%
Interest Coverage
— 0.00 0.00 0.00
Operating CF/Net income
— 0.57 0.42 0.46
Depreciation/Fixed assets
— 4.41 4.75 6.80
Capex/Depreciation
— 6.10 (0.05) 5.90
Revenue per Share
— 0.45 0.44 0.46
Operating CF per Share
— (0.76) (0.37) (0.27)
Capex per Share
— 0.71 (0.01) 0.87
Capex to Sales
— (1.58) 0.02 (1.88)
Net Profit Margin
— (297.95%) (201.30%) (128.59%)

Fold the line items

Columns are period end dates